文献速递血栓与止血

住院COVID-19患者血栓预防的通用临床决策支持工具:IMPROVE-DD集群随机试验的事后分析

Universal clinical decision support tool for thromboprophylaxis in hospitalized COVID-19 patients: post hoc analysis of the IMPROVE-DD cluster randomized trial.
PubMed 文献 · J Thromb Haemost · 2024-08-14

该研究为IMPROVE-DD集群随机试验的事后分析,评估嵌入IMPROVE-DD静脉血栓栓塞症评分的电子健康记录无关临床决策支持工具在4家纽约医院COVID-19住院患者中的效果。结果显示该工具与出院时适当延长期血栓预防率增加相关(42.6% vs 28.8%;OR 1.83),并与静脉血栓栓塞症、动脉血栓栓塞、总血栓栓塞及30天全因再入院/死亡减少相关,且未增加大出血。

要点

  • CDS工具采用率96.8%,与出院时适当延长期血栓预防率增加相关(42.6% vs 28.8%;OR 1.83)。
  • CDS与静脉血栓栓塞症(OR 0.54)、动脉血栓栓塞(OR 0.10)、总血栓栓塞(OR 0.50)减少相关。
  • CDS与30天全因再入院/死亡减少相关(OR 0.78),大出血、VTE相关再入院/死亡及全因死亡率无差异。

核心结论

  • 嵌入IMPROVE-DD VTE评分的电子健康记录无关CDS工具采用率高,与出院时适当延长期血栓预防增加相关,并减少血栓栓塞和全因再入院/死亡,且不增加大出血。

研究设计与样本

  • IMPROVE-DD集群随机试验的事后分析,评估COVID-19住院患者血栓预防CDS,4家纽约医院于2020年12月21日至2022年1月21日期间1:1随机分配至CDS(干预,n=2)或无CDS(常规护理,n=2)。

主要发现

  • CDS组采用率为96.8%。
  • CDS与出院时适当延长期血栓预防率增加相关(42.6% vs 28.8%;OR 1.83;95%CI 1.39-2.41;P<.001)。
  • CDS与VTE减少相关(OR 0.54;95%CI 0.39-0.75;P<.001)。
  • CDS与动脉血栓栓塞减少相关(OR 0.10;95%CI 0.01-0.81;P=.01)。
  • CDS与总血栓栓塞减少相关(OR 0.50;95%CI 0.36-0.69;P<.001),并与30天全因再入院/死亡减少相关(OR 0.78;95%CI 0.62-0.99;P=.04)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inpatient and extended postdischarge thromboprophylaxis of COVID-19 patients remains suboptimal despite antithrombotic guidelines. OBJECTIVES: To determine whether a novel electronic health record-agnostic clinical decision support (CDS) tool incorporating the International Medical Prevention Registry on Venous Thromboembolism plus D-dimer (IMPROVE-DD) venous thromboembolism (VTE) scores increases appropriate inpatient and extended postdischarge thromboprophylaxis and improves outcomes in COVID-19 inpatients. METHODS: This post hoc analysis of the IMPROVE-DD cluster randomized trial evaluated thromboprophylaxis CDS among COVID-19 inpatients at 4 New York hospitals between December 21, 2020, and January 21, 2022. Hospitals were randomized 1:1 to CDS (intervention, n = 2) vs no CDS (usual care, n = 2). The primary outcome was rate of appropriate thromboprophylaxis. Secondary outcomes included rates of major thromboembolism, all-cause and VTE-related readmissions and death, major bleeding (MB), and all-cause mortality 30 days after discharge. RESULTS: Two thousand four hundred fifty-two COVID-19 inpatients were analyzed (CDS, 1355; no CDS, 1097). Mean age was 73.7 ± 9.37 years; 50.1% of participants were male. CDS adoption was 96.8% (intervention group). CDS was associated with increased appropriate at-discharge extended thromboprophylaxis (42.6% vs 28.8%; odds ratio [OR], 1.83; 95% CI, 1.39-2.41; P < .001). CDS was associated with reduced VTE (OR, 0.54; 95% CI, 0.39-0.75; P < .001), arterial thromboembolism (OR, 0.10; 95% CI, 0.01-0.81; P = .01), total thromboembolism (OR, 0.50; 95% CI, 0.36-0.69; P < .001), and 30-day all-cause readmission/death (OR, 0.78; 95% CI, 0.62-0.99; P = .04). There were no differences in MB, VTE-related readmissions/death, or all-cause mortality. CONCLUSION: Electronic health record-agnostic CDS incorporating IMPROVE-DD VTE scores had high adoption, was associated with increased appropriate at-discharge extended thromboprophylaxis, and reduced thromboembolism and all-cause readmission/death without increasing MB in COVID-19 inpatients.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Goldin M, Tsaftaridis N, Koulas I, et al. Universal clinical decision support tool for thromboprophylaxis in hospitalized COVID-19 patients: post hoc analysis of the IMPROVE-DD cluster randomized trial. J Thromb Haemost. 2024. PMID: 39128654. doi:10.1016/j.jtha.2024.07.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。